Twenty-four Hour Hormone Profiles of TSH, Free T3 and Free T4 in Hypothyroid Patients on Combined T3/T4 Therapy
The DOI matches its Crossref record.
Abstract
The benefits of using thyroxine (T4) plus triiodothyronine (T3) in combination in thyroid hormone replacement are unproven but many individuals continue to be treated with this regime. When T3 is used alone for hypothyroidism, it results in wide fluctuations of thyroid hormone levels. However, only limited data exists on combined T3/T4 therapy. In this study, we have compared 24-hour profiles of thyroid stimulating hormone (TSH), free T4 (fT4) and free T3 (fT3) and cardiovascular parameters in 10 hypothyroid patients who had been on once daily combined T3/T4 therapy for more than 3 months with 10 patients on T4 alone. Twenty patients, who were part of a larger study, investigating the long-term benefits of combined T3/T4 therapy, were recruited into this sub-study. Over 24-hours, 12 samples were taken for thyroid hormones. Their 24-hour pulse and BP is also monitored on a separate occasion. On T4 alone, a modest 16% rise in fT4 with no change in fT3 was seen in the first 4-hours post-dose. In contrast, on combined treatment, fT3 levels showed a marked rise of 42% within the first 4-hours post-dose (T3/T4:T4=6.24: 4.63 mU/L, p<0.001). Mean exposure to fT3 calculated by area under the curve (AUC) was higher (T3/T4:T4=1148:1062, p<0.0001) on T3. Circadian rhythm of TSH was maintained on both treatments. No difference in pulse or blood pressure over the 24-hours was seen between the groups. Our data suggests that despite chronic combined T3/T4 therapy, wide peak-to-trough variation in fT3 levels persists. Although no immediate cardiovascular effects were seen, the long-term consequences for patients on combined therapy are unknown.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“suggesting that treatment-related unblinding due to cardiovascular effects is unlikely on low dose combination therapy (57).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [57]
In the citing paper
“Vital signs were not different between treatment groups in one substudy in which 24-hour pulse and blood pressure levels during monotherapy and combination therapy were specifically monitored”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [57]
In the citing paper
“With once-daily LT3 doses of 6.5–10 μg, up to a 40% increase in T3 levels can be seen after the LT3 tablet is taken (57,71).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [57]
In the citing paper
“This supports that combined therapy improves T3 levels, which could help patients with issues in the conversion of T4 to T3 in the peripheral tissues. [23].”
In the citing paper
“Whereas during L-T4 monotherapy no change in serum free T3 is seen in the first four hours post-dose, during L-T4 + L-T3 combination therapy a marked rise of 42% in serum free T3 has been observed within the first 4 h after ingestion of L-T3 [66] .”
From 2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism (2012) · cites this paper as [66]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Still being checked.
Cited by
2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism
Wiersinga, W. M., Duntas, L., Fadeyev, V., Nygaard, B., & Vanderpump, M. P. J. (2012) · European Thyroid Journal · doi:10.1159/000339444 · Cited by 437
Treatment with thyroid hormone
Biondi, B., & Wartofsky, L. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1083 · Cited by 259
Russell, W., Harrison, R. F., Smith, N., Darzy, K., Shalet, S., Weetman, A. P., & Ross, R. J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2674 · Cited by 219
Treatment for primary hypothyroidism: current approaches and future possibilities
Vaidya, B., Chakera, & Pearce (2011) · Drug Design, Development and Therapy · doi:10.2147/dddt.s12894 · Cited by 199
Ehrenkranz, J., Bach, P. R., Snow, G. L., Schneider, A., Lee, J. L., Ilstrup, S., Bennett, S. T., & Benvenga, S. (2015) · Thyroid · doi:10.1089/thy.2014.0589 · Cited by 190
“In contrast, the circadian TSH rhythm is not affected by treatment of hypothyroidism with either thyroxine (T4) or T3 (30).”
Jonklaas, J., Bianco, A. C., Cappola, A. R., Celi, F. S., Fliers, E., Heuer, H., McAninch, E. A., Moeller, L. C., Nygaard, B., Sawka, A. M., et al. (2021) · Thyroid® · doi:10.1089/thy.2020.0720 · Cited by 172
Self-citationDefending plasma T3 is a biological priority
Abdalla, S. M., & Bianco, A. C. (2014) · Clinical Endocrinology · doi:10.1111/cen.12538 · Cited by 147
Thyrotropin secretion patterns in health and disease
Roelfsema, F., & Veldhuis, J. D. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1076 · Cited by 113
Thyroxine alone or thyroxine plus triiodothyronine replacement therapy for hypothyroidism
Chao, M., Jiawei, X., Xia, H., Guoming, W., Yangang, W., Xufu, W., & Shuyao, Z. (2009) · Nuclear Medicine Communications · doi:10.1097/mnm.0b013e32832c79e0 · Cited by 93
Optimal thyroid hormone replacement
Jonklaas, J. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab031 · Cited by 89
Jonklaas, J., Bianco, A. C., Cappola, A. R., Celi, F. S., Fliers, E., Heuer, H., McAninch, E. A., Moeller, L. C., Nygaard, B., Sawka, A. M., et al. (2021) · European Thyroid Journal · doi:10.1159/000512970 · Cited by 78
Self-citationCeli, F. S., Zemskova, M., Linderman, J. D., Babar, N. I., Skarulis, M. C., Csako, G., Wesley, R., Costello, R., Penzak, S. R., & Pucino, F. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03700.x · Cited by 65
Levothyroxine: conventional and novel drug delivery formulations.
Liu, H., Li, W., Zhang, W., Sun, S., & Chen, C. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac030 · Cited by 63
Hypothyroidism: The difficulty in attributing symptoms to their underlying cause
Jansen, H. I., Boelen, A., Heijboer, A. C., Bruinstroop, E., & Fliers, E. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1130661 · Cited by 63
Dayan, C., & Panicker, V. (2018) · Thyroid Research · doi:10.1186/s13044-018-0045-x · Cited by 62
“[63], used with permission Dayan and Panicker Thyroid Research (2018) 11:1 Page 5 of 11”
BackgroundMethodSelf-citationvan der Spoel, E., Roelfsema, F., & van Heemst, D. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.619568 · Cited by 69
Rothacker, K. M., Brown, S. J., Hadlow, N. C., Wardrop, R., & Walsh, J. P. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-4011 · Cited by 51
Leow, M. K.-S., & Goede, S. L. (2014) · Theoretical Biology and Medical Modelling · doi:10.1186/1742-4682-11-35 · Cited by 51
“The models being proposed as more accurate varied from error function, fourth power polynomials to negative sigmoidal curves with inflexion points, and are all virtually based on aggregate analyses of clinical data of hundreds of thousands of different individuals [31-34].”
BackgroundSingle-Dose T3 Administration: Kinetics and Effects on Biochemical and Physiological Parameters
Jonklaas, J., Burman, K. D., Wang, H., & Latham, K. R. (2015) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000113 · Cited by 49
Hennessey, J. V., & Espaillat, R. (2018) · International Journal of Clinical Practice · doi:10.1111/ijcp.13062 · Cited by 49
Do we need still more trials on T4 and T3 combination therapy in hypothyroidism?
Wiersinga, W. M. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0879 · Cited by 45
Regulatory aspects of the human hypothalamus-pituitary-thyroid axis
Roelfsema, F., Boelen, A., Kalsbeek, A., & Fliers, E. (2017) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2017.09.004 · Cited by 49
The relevance of T3 in the management of hypothyroidism
Salvatore, D., Porcelli, T., Ettleson, M. D., & Bianco, A. C. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00004-3 · Cited by 41
Kaminski, J., Miasaki, F. Y., Paz-Filho, G., Graf, H., & Carvalho, G. A. D. (2016) · Archives of Endocrinology and Metabolism · doi:10.1590/2359-3997000000192 · Cited by 42
“Whereas a previous study showed that LT4 monotherapy leads to no change in serum free T3 in the first 4 hours post-dose, LT4/LT3 therapy can determine a marked rise by 42% in serum free T3 within the first 4 hours after ingestion of LT4/LT3 (27).”
BackgroundRoss, D. S. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13410 · Cited by 42
Jonklaas, J., & Burman, K. D. (2016) · Thyroid® · doi:10.1089/thy.2015.0629 · Cited by 41
“The fluctuation in free T3 (FT3) levels during LT4/LT3 combination with daily administration of 10 mcg LT3 has previously been shown in a study of 10 patients (11).”
Akirov, A., Fazelzad, R., Ezzat, S., Thabane, L., & Sawka, A. M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00477 · Cited by 37
Yi, W., Kim, B. H., Kim, M., Kim, J., Im, M., Ryang, S., Kim, E. H., Jeon, Y. K., Kim, S. S., & Kim, I. J. (2022) · Thyroid · doi:10.1089/thy.2021.0634 · Cited by 36
“31,32 At the serum T3 peak after LT3 administration, patients complained of palpitation and chest tightness, and recent clinical trials have reported minimally increased heart rate and systolic blood pressure in patients who received LT4/LT3 combination therapy.”
Thyroid Hormone Replacement Therapy: Three Simple Questions, Complex Answers
Bianco, A. C., & Casula, S. (2012) · European Thyroid Journal · doi:10.1159/000339447 · Cited by 32
Sustained release T3 therapy: animal models and translational applications
Idrees, T., Price, J. D., Piccariello, T., & Bianco, A. C. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00544 · Cited by 30
“In patients taking 10 ug of LT3, the serum T3 peak is approximately 40% above the baseline levels (32); multiple daily doses might partially mitigate this problem but its practicality is a challenge.”
BackgroundGoede, S. L., Leow, M. K.-S., Smit, J. W. A., Klein, H. H., & Dietrich, J. W. (2014) · Bulletin of Mathematical Biology · doi:10.1007/s11538-014-9955-5 · Cited by 30
Thyroid hormones regulate both cardiovascular and renal mechanisms underlying hypertension
Jankauskas, S. S., Morelli, M. B., Gambardella, J., Lombardi, A., & Santulli, G. (2020) · Journal of Clinical Hypertension · doi:10.1111/jch.14152 · Cited by 37
DiStefano, J., & Jonklaas, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00746 · Cited by 28
“In comparison, the Saravanan sub-study (34) reported 3 of 10 patients in the LT3/LT4 group, but none in the LT4 alone group, had FT3 levels above their laboratory reference range at some time over the 24-h period, but lasting only for<2 h.”
MethodResultRisks and safety of combination therapy for hypothyroidism
Jonklaas, J. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2016.1182019 · Cited by 27
Karami, P., Gholamin, D., & Ahar, M. J. (2023) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-023-04767-8 · Cited by 26
Da Conceição, R. R., Fernandes, G. W., Fonseca, T. L., Bocco, B. M. L. C., & Bianco, A. C. (2018) · Thyroid · doi:10.1089/thy.2018.0205 · Cited by 23
“Patients taking LT3 exhibit a substantial serum T3 peak (about 40% above baseline) three to four hours after dosing (15).”
Combination Thyroid Hormone Replacement; Knowns and Unknowns
Taylor, P. N., Eligar, V., Muller, I., Scholz, A., Dayan, C., & Okosieme, O. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00706 · Cited by 21
Self-citationDumitrescu, A. M., Hanlon, E. C., Arosemena, M., Duchon, O., Ettleson, M., Giurcanu, M., & Bianco, A. C. (2022) · Thyroid · doi:10.1089/thy.2021.0304 · Cited by 20
Fröhlich, E., & Wahl, R. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0713 · Cited by 23
Hong, K. H. (2014) · Korean Journal of Otorhinolaryngology - Head and Neck Surgery · doi:10.3342/kjorl-hns.2014.57.5.297 · Cited by 16
Increased fT4 concentrations in patients using levothyroxine without complete suppression of TSH
Jansen, H. I., Bult, M., Bisschop, P. H. L. T., Boelen, A., Heijboer, A. C., & Hillebrand, J. J. (2023) · Endocrine Connections · doi:10.1530/ec-22-0538 · Cited by 14
Nassar, M., Hassan, A., Ramadan, S., Desouki, M. T., Hassan, M. A., & Chaudhuri, A. (2024) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01612-6 · Cited by 12
“Our results reveal that combined T4 + T3 therapy does not significantly alter TSH levels, yet it influences free T3 levels, aligning with findings from previous research [23].”
ResultSarapura, V. D., Gordon, D. F., & Samuels, M. H. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-380926-1.10006-9 · Cited by 13
The 10 top prescribed medicines in Germany from 1985 to 2022: pharmacological analysis
Schröder, L., & Seifert, R. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03615-5 · Cited by 12
Riis, K. R., Larsen, C. B., & Bonnema, S. J. (2024) · Thyroid® · doi:10.1089/thy.2023.0649 · Cited by 10
Sarapura, V. D., & Samuel, M. H. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804169-7.00006-4 · Cited by 11
Vargas‐Uricoechea, H., & Wartofsky, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179218 · Cited by 15
Ji, C., Ou, Y., Yu, W., Lv, J., Zhang, F., Li, H., Gu, Z., Li, J., Zhong, Z., & Wang, H. (2023) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2023.05.015 · Cited by 8
Penna, G. C., Bianco, A. C., & Ettleson, M. D. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad629 · Cited by 8
Role of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism
Jonklaas, J. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.12.003 · Cited by 10
Premawardhana, L. D., Taylor, P. N., Okosieme, O. E., Adlan, M. A., Obuobie, E. K., & Dayan, C. M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1282608 · Cited by 6
Self-citationTotal Thyroidectomy and Subsequent Weight Gain in Pediatric Populations
Edwards, E. R., Hazkani, I., Stein, E., Josefson, J. L., Samis, J. H., Miller, J. L., & Rastatter, J. C. (2022) · The Laryngoscope · doi:10.1002/lary.30532 · Cited by 6
Study the Protective Effect of Ginger against the Toxicity of Dimethoate on Hormones in Rabbits
Elgazwi, S. M., Khaled, F. A., & Alsanous, M. F. (2021) · Asian Journal of Research in Biochemistry · doi:10.9734/ajrb/2021/v8i330181 · Cited by 6
Jonklaas, J. (2019) · Springer eBooks · doi:10.1007/978-3-319-72102-6_19 · Cited by 6
Shared Decisionmaking in the Treatment of Hypothyroidism
Bianco, A. C. (2025) · Clinical Endocrinology · doi:10.1111/cen.15228 · Cited by 7
Mehran, L., Amouzegar, A., Foroutan, S. M., Masoumi, S., Tohidi, M., Abdi, H., Aghaei, A., Saghafinia, A. E., & Azizi, F. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01434-y · Cited by 6
Goede, S. L., Latham, K. R., Leow, M. K., & Jonklaas, J. (2017) · Journal of Biological Systems · doi:10.1142/s0218339017500073 · Cited by 5
Liquid liothyronine to obtain target TSH in differentiated thyroid cancer patients
Trimboli, P., Centanni, M., & Virili, C. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej16-0040 · Cited by 4
Chaker, L., & Peeters, R. P. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99899-4.00015-9 · Cited by 9
Intramuscular and subcutaneous levothyroxine: success in treating refractory hypothyroidism
Chaudhury, N., Crasto, W., Saravanan, P., & Patel, V. (2025) · European Thyroid Journal · doi:10.1530/etj-25-0012 · Cited by 6
Self-citationClinical Significace of Thyrotropin Variability
Sviridonova, M. A., & Fadeyev, V. V. (2008) · Clinical and experimental thyroidology · doi:10.14341/ket20084416-24 · Cited by 5
Büber, İ., Eraydın, A., Sevgican, C. İ., Tekin, I., Kılıç, İ. D., & Fenkçi, S. M. (2023) · Endocrine · doi:10.1007/s12020-023-03363-1 · Cited by 2
Thyroiditis and Other More Unusual Forms of Hyperthyroidism
Meek, S., & Smallridge, R. C. (2009) · CRC Press eBooks · doi:10.3109/9781420070651-4 · Cited by 2
Bonnema, S. J., Riis, K. R., Jensen, C. Z., Thvilum, M., & Nygaard, B. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab778 · Cited by 2
Is euthyroidism within reach for all?
Jonklaas, J. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2267120 · Cited by 2
Hedberg, F., Lindh, J. D., Mannheimer, B., Planck, T., Skov, J., Falhammar, H., & Calissendorff, J. (2026) · Journal of the Endocrine Society · doi:10.1210/jendso/bvag107 · Cited by 1
Pharmacodynamic Evaluation: Endocrinology
Sandow, J. (2010) · Springer eBooks · doi:10.1007/978-3-540-89891-7_35 · Cited by 2
Options of Replacement Therapy in Hypothyroidism
Valentine, V., Galina, A., & Morgunov, T. (2012) · InTech eBooks · doi:10.5772/31226 · Cited by 1
Impact of isolated TSH levels in and out of normal range on different tissues
Wahl, R. (2016) · European Journal of Endocrinology · doi:10.15496/publikation-16920 · Cited by 1
Integrative Approaches to Patients Undergoing Thyroid Surgery
Olson, B. R. (2017) · Springer eBooks · doi:10.1007/978-3-319-43618-0_23 · Cited by 2
The Laboratory Approach to Thyroid Disorders
Sherman, S. I. (2009) · CRC Press eBooks · doi:10.3109/9781420070651-2 · Cited by 1
Hasoon, D. S., Hadi, M. A., Naji, T. F., & Bahrami, A. M. (2022) · International Journal of Health Sciences · doi:10.53730/ijhs.v6ns3.7762 · Cited by 1
Azizi, F., Moeini, A. S. H., Mehran, L., Masoumi, S., Abdi, H., Foroutan, S. M., Saghafinia, A. E., & Amouzegar, A. (2025) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2025.100395 · Cited by 4
Ziegler, R., & Schwabe, U. (2008) · Springer eBooks · doi:10.1007/978-3-540-69219-5_41 · Cited by 1
Modalities of Thyroid Hormone Administration and Correlates Between Blood and Tissue Levels
Celi, F. S. (2020) · Springer eBooks · doi:10.1007/978-3-030-36871-5_26
Essentials of Thyroid Hormone Treatment in Differentiated Thyroid Cancer
Aydoğan, B. İ., & Gürsoy, A. (2021) · Nuclear Medicine Seminars · doi:10.4274/nts.galenos.2021.0002 · Cited by 1
EXTENDED ABSORPTION OF LIOTHYRONINE FROM POLY-ZINC-LIOTHYRONINE (PZL) IN HUMANSPreprint
Dumitrescu, A. M., Hanlon, E. C., Arosemena, M., Duchon, O., Ettleson, M. D., Giurcanu, M. C., & Bianco, A. C. (2021) · medRxiv · doi:10.1101/2021.06.14.21258437
Ziegler, R., & Schwabe, U. (2013) · Springer eBooks · doi:10.1007/978-3-642-37124-0_41
Kasperk, H. C. (2021) · Springer eBooks · doi:10.1007/978-3-662-63825-5_41
Ziegler, R., & Schwabe, U. (2014) · Springer eBooks · doi:10.1007/978-3-662-43487-1_41
(2008) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e328311f3cb
Krátký, J. (2022) · Vnitřní lékařství · doi:10.36290/vnl.2022.010 · Cited by 1
Ziegler, R., & Kasperk, H. C. (2019) · Springer eBooks · doi:10.1007/978-3-662-59046-1_43
Ziegler, R., & Schwabe, U. (2015) · Springer eBooks · doi:10.1007/978-3-662-47186-9_40
Ziegler, R., & Kasperk, C. H. (2018) · Springer eBooks · doi:10.1007/978-3-662-57386-0_43
Ziegler, R., & Kasperk, C. H. (2017) · Springer eBooks · doi:10.1007/978-3-662-54630-7_43
Ziegler, R., & Schwabe, U. (2012) · Springer eBooks · doi:10.1007/978-3-642-29242-2_41
Ziegler, R., & Kasperk, H. C. (2020) · Springer eBooks · doi:10.1007/978-3-662-62168-4_40
Ziegler, R., & Schwabe, U. (2009) · Springer eBooks · doi:10.1007/978-3-642-01080-4_41
Ziegler, R., & Schwabe, U. (2010) · Springer eBooks · doi:10.1007/978-3-642-13380-0_41
Ziegler, R., & Kasperk, C. H. (2016) · Springer eBooks · doi:10.1007/978-3-662-50351-5_43
Ziegler, R., & Schwabe, U. (2011) · Springer eBooks · doi:10.1007/978-3-642-21992-4_41
Tsareva, Y. O., & Шварц, Ю. Г. (2020) · Кардиология в Беларуси · doi:10.34883/pi.2020.12.1.010
Kasperk, H. C. (2022) · Springer eBooks · doi:10.1007/978-3-662-66303-5_37
Ito, M., & Akamizu, T. (2023) · Clinical Thyroidology · doi:10.1089/ct.2023;35.402-404
Protective Roles of Neem Leaves on Hormonal Levels in Heteroclarias Exposed to Diclofenac
Abdulkareem, S. I., & Abdulkareem, A. O. (2024) · Egyptian Academic Journal of Biological Sciences. B, Zoology · doi:10.21608/eajbsz.2024.400571
Mehran, L., Amouzegar, A., Foroutan, S. M., Masoumi, S., Tohidi, M., Abdi, H., Aghaei, A., Saghafinia, A. E., & Azizi, F. (2024) · Figshare · doi:10.6084/m9.figshare.26613242
Nassar, M., Hassan, A., Ramadan, S., Desouki, M., Hassan, M. A., & Chaudhuri, A. (2024) · Figshare · doi:10.6084/m9.figshare.26733783
Stedman, M., Taylor, P. N., Halsall, I., Halsall, D. J., Okosieme, B., Bahl, S., Veluchamy, S., Premawardhana, L. D. K. E., Fryer, A. A., Dayan, C. M., et al. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70214
Self-citationDelivery of liothyronine by microneedle patch for the treatment of hypothyroidism
Gomaa, Y. A., Hasin, T., Griffin, M. N., Nguyen, T. C., Noel, R. K., O’Farrell, L., McAninch, E. A., Kaiser, A. M., Wood, L. B., & Prausnitz, M. R. (2026) · Drug Delivery and Translational Research · doi:10.1007/s13346-026-02214-6
Metadata
- Authors
- Saravanan, P., Siddique, H., Simmons, D., Greenwood, R., & Dayan, C.
- Affiliations
- University of Bristol (GB)
- Venue
- Experimental and Clinical Endocrinology & Diabetes
- Publisher
- Georg Thieme Verlag KG
- Published
- 2007-05-03
- Volume
- 115
- Issue
- 04
- Pages
- 261-267
- ISSN
- 0947-7349 (ISSN-L)
- 1439-3646
- OpenAlex
- W2024747445
- Cited by
- 100
- References
- 0
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 7 · 2023: 10 · 2022: 9 · 2021: 10 · 2020: 5 · 2019: 6 · 2018: 4 · 2017: 5 · 2016: 7 · 2015: 3 · 2014: 7 · 2013: 2 · 2012: 4
- FWCI
- 3.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Experimental and Clinical Endocrinology & Diabetes (publishedVersion)
- PubMed (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- hypothyroidism, triiodothyronine, thyroxine, free T3, free thyroxine, thyroid-stimulating hormone, circadian rhythm, thyroid hormone replacement, cardiovascular parameters, heart rate, blood pressure
- MeSH terms
- Adult, Aged, Blood Pressure, Circadian Rhythm, Double-Blind Method, Humans, Hypothyroidism, Middle Aged, Placebos, Pulse, Thyrotropin, Thyroxine, Triiodothyronine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.